Neumora Therapeutics (NMRA) Accumulated Expenses (2022 - 2026)

Neumora Therapeutics has reported Accumulated Expenses for 5 years, with the latest figure at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 21.74% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (down 21.74% YoY), and the FY2025 full-year result was $11.5 million, up 15.23% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $4.8 million, down from $11.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $25.0 million in Q3 2025, with the low at $4.7 million in Q1 2024.
• Average Accumulated Expenses over 5 years is $13.6 million, with a median of $10.7 million recorded in 2024.
• Year-over-year, Accumulated Expenses soared 153.06% in 2023 and sank 63.69% in 2025.
• Tracing NMRA's Accumulated Expenses over 5 years: stood at $8.4 million in 2022, then soared by 153.06% to $21.3 million in 2023, then sank by 53.07% to $10.0 million in 2024, then gained by 15.23% to $11.5 million in 2025, then tumbled by 58.07% to $4.8 million in 2026.
• The last three Accumulated Expenses figures came in at $4.8 million (Q1 2026), $11.5 million (Q4 2025), and $25.0 million (Q3 2025), per Business Quant data.

Peer Comparison